Catalyst Pharmaceutical Partners Appoints Dr. Bernardino Mosquera as Vice President of Clinical Operations

Catalyst Pharmaceutical Partners Appoints Dr. Bernardino Mosquera as Vice
President of Clinical Operations

CORAL GABLES, Fla., March 5, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical
Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on
the development and commercialization of novel prescription drugs targeting
rare (orphan) neurological diseases and disorders, is pleased to announce
today the appointment of Bernardino Mosquera, M.D. as Vice President of
Clinical Operations. Dr. Mosquera will be responsible for the operational
oversight of Catalyst's clinical trials and the management of collaborations
with clinical service providers such as clinical research organizations (CROs)
and central laboratories.

"With our ongoing Phase III trial of Firdapse^TM for the treatment of LEMS,
this is an excellent time to welcome someone of Dr. Mosquera's caliber to our
management team," said Steven Miller, Ph.D., Chief Operating Officer of
Catalyst. "Dr. Mosquera's past experience will be an invaluable addition to
our clinical programs, and we look forward to working with him."

For the past three years, Dr. Mosquera has been managing his own clinical
research consulting company. As an independent consultant, he was involved in
trials for Alzheimer's, Parkinson's, and stroke medications for a
multinational pharmaceutical company and several biotech companies. Prior to
his independent experience, he spent five years, first at Amgen, then as a
dedicated contractor for Amgen, on a number of phase III trials in the
oncology area. Prior to joining Amgen, he was with Kos Pharmaceuticals up
until its acquisition by Abbott where he was involved in all aspects of
clinical trial management for two Phase III trials for a hyperlipidemia
treatment. This experience included CRO selection, site selection, vendor
management, creating all study documents, IRB submissions, trial management,
and CRA management.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc., is a specialty pharmaceutical company
focused on the development and commercialization of prescription drugs
targeting rare (orphan) neurological diseases and disorders, including
Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette's
disorder. Catalyst's lead candidate, Firdapse™ for the treatment of LEMS, is
currently undergoing testing in a global, multi-center, pivotal phase III
trial. Catalyst is also developing a potentially safer and more potent
vigabatrin analog (designated CPP-115 by Catalyst) to treat infantile spasms,
and epilepsy, as well as other neurological conditions associated with reduced
GABAergic signaling, like post-traumatic stress disorder, Tourette's disorder,
and movement disorders associated with the treatment of Parkinson's Disease.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking
statements involve known and unknown risks and uncertainties, which may cause
the Company's actual results in future periods to differ materially from
forecasted results. A number of factors, including whether any of the
Company's product candidates will ever be approved for commercialization and
those factors described in the Company's filings with the U.S. Securities and
Exchange Commission (SEC), could adversely affect the Company. Copies of the
Company's filings with the SEC are available from the SEC, may be found on the
Company's website or may be obtained upon request from the Company. The
Company does not undertake any obligation to update the information contained
herein, which speaks only as of this date.

CONTACT: For Further Information Contact:
         Patrick J. McEnany
         Catalyst Pharmaceutical Partners
         Chief Executive Officer
         (305) 529-2522
         pmcenany@catalystpharma.com
        
         Melody Carey
         Rx Communications Group
         Co-President
         (917) 322-2571
         mcarey@rxir.com
 
Press spacebar to pause and continue. Press esc to stop.